Condition
Obesity
Overweight
Locations
United States
Start date
29/05/2026
Identifiers
Trial ID NN9833-8420,
NCT number NCT07607587,
Eudract number Not Available
NCT number NCT07607587,
Eudract number Not Available
Summary
The purpose of this clinical study is to look at the safety of the medicine Cagrilintide when compared to placebo in people who do not tolerate marketed glucagon-like peptide-1 (GLP-1) therapies and who live with overweight or obesity. Participants will get either Cagrilintide (the treatment being tested) or Placebo (a treatment that has no active medicine in it). Which treatment participant will get is decided by chance. The study will last for about 8 months.
Trial Overview:
Treatment
DRUG: Cagrilintide
DRUG: Placebo (matched to Cagrilintide)
Study type
INTERVENTIONAL
Trial duration
May 29 2026 - Nov 19 2027
Participants
114
Phase
I
Are you eligible?
Gender
Male and female
Age
18 years and older
Find out how you can participate
Questions or concerns
Do you have any question about what it’s like being a clinical volunteer? Have a look at our answers to frequently asked questions.
This site contains information about clinical trials sponsored by Novo Nordisk. It is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. The information on this site should not be relied on as the basis for any decision or action. Only a physician can determine whether a specific product is correct for a particular patient. If you have questions regarding any information contained on this site you should consult a physician.